KR930701588A - 재조합 구두 바이러스 백신 - Google Patents
재조합 구두 바이러스 백신Info
- Publication number
- KR930701588A KR930701588A KR1019920703430A KR920703430A KR930701588A KR 930701588 A KR930701588 A KR 930701588A KR 1019920703430 A KR1019920703430 A KR 1019920703430A KR 920703430 A KR920703430 A KR 920703430A KR 930701588 A KR930701588 A KR 930701588A
- Authority
- KR
- South Korea
- Prior art keywords
- virus
- oral
- disease
- dna
- gene
- Prior art date
Links
- 241000700605 Viruses Species 0.000 title claims abstract 21
- 229960005486 vaccine Drugs 0.000 title claims 6
- 101150034814 F gene Proteins 0.000 claims abstract description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract 17
- 201000010099 disease Diseases 0.000 claims abstract 9
- 108020004440 Thymidine kinase Proteins 0.000 claims abstract 3
- 230000003612 virological effect Effects 0.000 claims abstract 2
- 238000004113 cell culture Methods 0.000 claims 7
- 241000271566 Aves Species 0.000 claims 4
- 210000003527 eukaryotic cell Anatomy 0.000 claims 3
- 208000015181 infectious disease Diseases 0.000 claims 3
- 241000287828 Gallus gallus Species 0.000 claims 2
- 108091000080 Phosphotransferase Proteins 0.000 claims 2
- 239000003937 drug carrier Substances 0.000 claims 2
- 241000700618 Vaccinia virus Species 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 210000001161 mammalian embryo Anatomy 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 102000020233 phosphotransferase Human genes 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- 210000004927 skin cell Anatomy 0.000 claims 1
- 102000006601 Thymidine Kinase Human genes 0.000 abstract 1
- 208000010717 cat disease Diseases 0.000 description 1
- 210000000078 claw Anatomy 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
- C12N2710/24141—Use of virus, viral particle or viral elements as a vector
- C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18111—Avulavirus, e.g. Newcastle disease virus
- C12N2760/18122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Virology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Public Health (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Animal Behavior & Ethology (AREA)
- Gastroenterology & Hepatology (AREA)
- General Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Plant Pathology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Immunology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
본 발명은 구두바이러스에 선천적으로 존재하지 않는 DNA가 구두바이러스게놈의 비-필수영역에 존재함으로써 합성적으로 변형된 재조합 구두바이러스를 제공한다. 본 발명의 바람직한 양태로서, 뉴우캣슬병 바이러스 F유전자가 구두게놈내의 티미딘 키나제좌내에 삽입됨으로써 F 유전자의 적어도 일부에 의해 구두 바이러스가 변형된다.
Description
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음
제1도는 뉴우캣슬병 F 유전자를 암호화하는 mRNA 클로 II. 14의 삽입체의 뉴클레오타이드 서열을 나타낸 것이다.
Claims (16)
- 구두바이러스에 선천적으로 존재하지 않는 DNA가 구두바이러스게놈의 비-필수영역에 존재함으로써 합성적으로 변형된 재조합 구두바이러스.
- 제1항에 있어서, 언급된 비-필수영역이 티미딘 키나제 유전자내에 존재하는 구두바이러스.
- 제1항에 있어서, 구두바이러스에 선천적으로 존재하지 않는 언급된 DNA가 뉴우캣슬병 바이러스 F유전자의 적어도 일부인 구두바이러스.
- 제2항에 있어서, 구두바이러스에 선천적으로 존재하지 않는 언급된 DNA가 뉴우캣슬병 바이러스 F유전자의 적어도 일부인 구두바이러스.
- 구두바이러스에 선천적으로 존재하지 않는 DNA가 구두바이러스게놈의 비-필수영역에 존재함으로써 합성적으로 변형된 재조합 구두바이러스를 함유하는 백신.
- 제5항에 있어서, 구두게놈의 비-필수영역이 티미딘키나제 유전자내에 존재하는 백신.
- 제5항에 있어서, 구두바이러스에 선천적으로 존재하지 않는 DNA가 뉴우캣슬병 바이러스 F유전자의 적어도 일부인 백신.
- (a) 목적하는 유전자 생성물의 암호화 외래 DNA를 적어도 하나의 백시니아 바이러스 프로모터의 조절하에 구두바이러스 티미닌 키나제 유전자의 플랭킹 서열내에 제공하고, (b) 단계 (a)의 DNA를 구두바이러스의 티미딘 키나제좌내로 도입시킴을 특징으로 하여 조류병의 예방용백신을 제조하는 방법.
- 제8항에 있어서, 외래 DNA가 뉴우캣슬병 바이러스 F유전자의 적어도 일부인 방법.
- 제1항의 구두바이러스와 약제학적으로 허용되는 담체를 함유하는 약제.
- 제4항의 백신과 약제학적으로 허용되는 담체를 함유하는 약제.
- 뉴우캣슬병 바이러스에 의한 감염에 민감한 조류에게 뉴우캣슬병 바이러스에 의한 조류의 감염을 억제하는데 유효한 양의 제14항에 따른 백신을 투여함을 특징으로하여, 뉴우캣슬병 바이러스에 의한 감염에 민감한 조류를 백신화 하는 방법.
- 제1항의 바이러스로 감염된 진핵세포 배양물.
- 제13항에 있어서, 언급된 세포배양물이 닭세포 배양물인 진핵세포 배양물.
- 제14항에 있어서, 언급된 세포배양물이 닭배 피부세포배양물인 진핵세포배양물.
- ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US54747090A | 1990-07-02 | 1990-07-02 | |
US547,470 | 1990-07-02 | ||
PCT/US1991/004675 WO1992000372A1 (en) | 1990-07-02 | 1991-07-01 | Recombinant pigeon pox virus vaccine |
Publications (1)
Publication Number | Publication Date |
---|---|
KR930701588A true KR930701588A (ko) | 1993-06-12 |
Family
ID=24184753
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1019920703430A KR930701588A (ko) | 1990-07-02 | 1991-07-01 | 재조합 구두 바이러스 백신 |
Country Status (6)
Country | Link |
---|---|
EP (1) | EP0537232A4 (ko) |
JP (1) | JPH05508540A (ko) |
KR (1) | KR930701588A (ko) |
AU (1) | AU8213391A (ko) |
CA (1) | CA2084064A1 (ko) |
WO (1) | WO1992000372A1 (ko) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0646172A4 (en) * | 1992-06-16 | 1997-07-02 | Commw Scient Ind Res Org | RECOMBINANT ENTOMOPHILIC VIRUSES. |
JPH08116976A (ja) * | 1994-10-20 | 1996-05-14 | Chemo Sero Therapeut Res Inst | 免疫用核酸調製物およびこれを用いた免疫方法 |
US6241991B1 (en) * | 1998-03-05 | 2001-06-05 | Akzo Nobel N.V. | Aviadenovirus |
CN107630036A (zh) * | 2017-10-16 | 2018-01-26 | 佛山科学技术学院 | 一种番鸭细小病毒vp1基因重组鸽痘病毒转移载体 |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3429965A (en) * | 1966-08-01 | 1969-02-25 | Sterling Drug Inc | Avian pox virus vaccine and process of preparing same |
WO1988002022A1 (en) * | 1986-09-22 | 1988-03-24 | Commonwealth Scientific And Industrial Research Or | Recombinant poxviruses |
CA1340203C (en) * | 1987-09-16 | 1998-12-15 | Noboru Yanagida | Recombinant apivoxvirus |
WO1990007581A1 (fr) * | 1988-12-29 | 1990-07-12 | Nippon Zeon Co., Ltd. | Promoteur, plasmide le contenant, et avipoxvirus de recombinaison |
JP2781605B2 (ja) * | 1989-06-22 | 1998-07-30 | 日本ゼオン株式会社 | 組み換えアビポックスウイルス |
-
1991
- 1991-07-01 KR KR1019920703430A patent/KR930701588A/ko not_active Application Discontinuation
- 1991-07-01 EP EP19910912297 patent/EP0537232A4/en not_active Withdrawn
- 1991-07-01 AU AU82133/91A patent/AU8213391A/en not_active Abandoned
- 1991-07-01 CA CA002084064A patent/CA2084064A1/en not_active Abandoned
- 1991-07-01 WO PCT/US1991/004675 patent/WO1992000372A1/en not_active Application Discontinuation
- 1991-07-01 JP JP91511819A patent/JPH05508540A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
AU8213391A (en) | 1992-01-23 |
JPH05508540A (ja) | 1993-12-02 |
CA2084064A1 (en) | 1992-01-03 |
EP0537232A4 (en) | 1993-06-30 |
EP0537232A1 (en) | 1993-04-21 |
WO1992000372A1 (en) | 1992-01-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Kibenge et al. | Biochemistry and immunology of infectious bursal disease virus | |
ES2061708T3 (es) | Virus recombinante de la viruela de la gallina, vectores de expresion de proteinas heterologas y vacunas para aves de corral derivadas de este virus. | |
Burdeinick-Kerr et al. | Synergistic roles of antibody and interferon in noncytolytic clearance of Sindbis virus from different regions of the central nervous system | |
KR910012233A (ko) | 칠면조의 재조합 포진바이러스와 그것에서 유도한 생존상태의 벡터 백신류 | |
CA2293612A1 (en) | Regulation of transcription in mammalian cells and viral replication by a tetracyclin repressor | |
ES2075901T3 (es) | Sistemas de expresion de virus recombinantes de arn con cadena negativa y vacunas. | |
WO2001089559A3 (en) | Porcine reproductive and respiratory syndrome virus (prrsv) recombinant avipoxvirus vaccine | |
Tham et al. | Apoptosis in cell cultures induced by infectious bursal disease virus following in vitro infection | |
ES2061850T3 (es) | Virus recombinante de la enfermedad de marek, su procedimiento de preparacion y vacuna. | |
NO954135D0 (no) | Fiskebukspyttkjertel-sykdomsvirus | |
KR930701588A (ko) | 재조합 구두 바이러스 백신 | |
RU2002100209A (ru) | Gm-csf лошади | |
WO1997003187A3 (en) | Marek's disease virus genes and their use in vaccines for protection against marek's disease | |
AU657144B2 (en) | Recombinant Marek's disease virus, process for preparing the same and vaccine containing the same | |
DE3789525T2 (de) | Das F-Protein vom AIDS-Virus enthaltender Impfstoff. | |
ES2078642T3 (es) | Vacuna recombinante contra la enfermedad de marek. | |
ATE323767T1 (de) | Impfstoff für die infektiöse peritonitis der katzen | |
ATE276360T1 (de) | Verwendung pharmazeutischer zusammensetzungen zur behandlung von neurodegenerativen krankheiten | |
HUT56881A (en) | Process for expressing human nerve growth factor in arthropoda frugiperda cells infected with recombinant baculovirus | |
Centers for Disease Control and Prevention (CDC | Availability of new rabies vaccine for human use | |
HUP9802974A1 (hu) | Fertőző bursitis elleni DNS-vakcina | |
Weder et al. | Induction of a host-specific chromatin-associated glycopolypeptide by human cytomegalovirus | |
Morgan et al. | Recombinant vaccine against Marek's disease | |
ATE102252T1 (de) | Rekombinantes gefluegelpockenvirus, expressionsvektoren fuer heterologische proteine und davon derivierte gefluegelvakzine. | |
TH50268A3 (th) | การปลูกวัคซีนเพสติไวรัส |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WITN | Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid |